{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch0\stshfloch0\stshfhich0\stshfbi0\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial;}
{\f34\fbidi \froman\fcharset0\fprq2{\*\panose 02040503050406030204}Cambria Math;}{\f40\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604030504040204}Verdana;}{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}
{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}
{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f515\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\f516\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\f518\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\f519\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\f520\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\f521\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}
{\f522\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\f523\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\f525\fbidi \fswiss\fcharset238\fprq2 Arial CE;}{\f526\fbidi \fswiss\fcharset204\fprq2 Arial Cyr;}
{\f528\fbidi \fswiss\fcharset161\fprq2 Arial Greek;}{\f529\fbidi \fswiss\fcharset162\fprq2 Arial Tur;}{\f530\fbidi \fswiss\fcharset177\fprq2 Arial (Hebrew);}{\f531\fbidi \fswiss\fcharset178\fprq2 Arial (Arabic);}
{\f532\fbidi \fswiss\fcharset186\fprq2 Arial Baltic;}{\f533\fbidi \fswiss\fcharset163\fprq2 Arial (Vietnamese);}{\f855\fbidi \froman\fcharset238\fprq2 Cambria Math CE;}{\f856\fbidi \froman\fcharset204\fprq2 Cambria Math Cyr;}
{\f858\fbidi \froman\fcharset161\fprq2 Cambria Math Greek;}{\f859\fbidi \froman\fcharset162\fprq2 Cambria Math Tur;}{\f862\fbidi \froman\fcharset186\fprq2 Cambria Math Baltic;}{\f863\fbidi \froman\fcharset163\fprq2 Cambria Math (Vietnamese);}
{\f915\fbidi \fswiss\fcharset238\fprq2 Verdana CE;}{\f916\fbidi \fswiss\fcharset204\fprq2 Verdana Cyr;}{\f918\fbidi \fswiss\fcharset161\fprq2 Verdana Greek;}{\f919\fbidi \fswiss\fcharset162\fprq2 Verdana Tur;}
{\f922\fbidi \fswiss\fcharset186\fprq2 Verdana Baltic;}{\f923\fbidi \fswiss\fcharset163\fprq2 Verdana (Vietnamese);}{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}
{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}
{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}
{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}
{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}
{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}
{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}
{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}
{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}}
{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;
\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;\red0\green0\blue0;\red255\green255\blue255;\red200\green16\blue46;\red120\green120\blue120;\red102\green102\blue102;}
{\*\defchp }{\*\defpap \ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 
\ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive \ssemihidden \spriority0 Default Paragraph Font;}{\*
\ts11\tsrowd\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv 
\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 \fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \spriority0 Normal Table;}{
\s15\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext15 \sqformat \spriority0 Normal_0;}}
{\*\rsidtbl \rsid3346355\rsid4273949}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapRight1\mintLim0\mnaryLim1}{\info{\author Romero, Cesar (Associated)}{\operator Romero, Cesar (Associated)}
{\creatim\yr2020\mo1\dy16\hr11\min32}{\revtim\yr2020\mo1\dy16\hr11\min32}{\version2}{\edmins0}{\nofpages1}{\nofwords6968}{\nofchars39724}{\nofcharsws46599}{\vern2073}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}
\paperw12240\paperh15840\margl720\margr720\margt720\margb720\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont0\relyonvml0\donotembedlingdata1\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1\noxlattoyen
\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin600\dgvorigin0\dghshow1\dgvshow1
\jexpand\viewkind5\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\snaptogridincell\allowfieldendsel\wrppunct
\asianbrkrule\nojkernpunct\rsidroot3346355\utinl \fet0{\*\wgrffmtfilter 013f}\ilfomacatclnup0\stylesortmethod0{\*\ftnsep \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid4273949 \chftnsep 
\par }}{\*\ftnsepc \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 
\ltrch\fcs0 \insrsid4273949 \chftnsepc 
\par }}{\*\aftnsep \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 
\ltrch\fcs0 \insrsid4273949 \chftnsep 
\par }}{\*\aftnsepc \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 
\ltrch\fcs0 \insrsid4273949 \chftnsepc 
\par }}\ltrpar \sectd \ltrsect\linex0\headery400\footery400\colsx708\endnhere\titlepg\sectlinegrid360\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 Contents}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid4273949 

\par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 
\par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid3346355 {\shp{\*\shpinst\shpleft0\shptop0\shpright10800\shpbottom0\shpfhdr0\shpbxcolumn\shpbxignore\shpbypara\shpbyignore\shpwr3\shpwrk0\shpfblwtxt0\shpz1\shplid2052
{\sp{\sn shapeType}{\sv 20}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn fFillOK}{\sv 0}}{\sp{\sn fNoFillHitTest}{\sv 0}}{\sp{\sn lineWidth}{\sv 12700}}
{\sp{\sn dhgt}{\sv 251658240}}{\sp{\sn fEditedWrap}{\sv 0}}{\sp{\sn fBehindDocument}{\sv 0}}{\sp{\sn fIsButton}{\sv 0}}{\sp{\sn fPseudoInline}{\sv 0}}{\sp{\sn fLayoutInCell}{\sv 1}}}{\shprslt{\*\do\dobxcolumn\dobypara\dodhgt8193
\dpline\dpptx0\dppty0\dpptx10800\dppty0\dpx0\dpy0\dpxsize10800\dpysize0\dplinew20\dplinecor0\dplinecog0\dplinecob0}}}}{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 
\par }}{\footerr \ltrpar \ltrrow\trowd \lastrow \ltrrow\ts11\trgaph108\trrh200\trleft0\trbrdrt\brdrs\brdrw10 \trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trbrdrh\brdrs\brdrw10 \trbrdrv\brdrs\brdrw10 
\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx8000\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10600\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs18\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 
\par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs14\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 \hich\f1 COPYRIGHT \'a9\loch\f1  2019 S&P Global Market Intelligence, a division of S&P Global Inc. All rights reserved
\par }\pard \ltrpar\ql \li0\ri0\sl200\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 
 HYPERLINK "https://marketintelligence.spg\hich\af1\dbch\af1\loch\f1 lobal.com/" }}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 spglobal.com/marketintelligence}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs14\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 \cell }\pard \ltrpar\qr \li0\ri0\sl340\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 
{\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 PAGE}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 
\hich\af1\dbch\af1\loch\f1 2}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 \cell }\pard \ltrpar
\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 \trowd \lastrow \ltrrow\ts11\trgaph108\trrh200\trleft0\trbrdrt\brdrs\brdrw10 
\trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trbrdrh\brdrs\brdrw10 \trbrdrv\brdrs\brdrw10 
\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx8000\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10600\row }\pard \ltrpar\ql \li0\ri0\sl100\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid4273949 
\par }}{\headerf \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 
\ltrch\fcs0 \cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1  }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid4273949 
\par }}{\footerf \ltrpar \ltrrow\trowd \lastrow \ltrrow\ts11\trgaph108\trrh200\trleft0\trbrdrt\brdrs\brdrw10 \trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trbrdrh\brdrs\brdrw10 \trbrdrv\brdrs\brdrw10 
\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx8000\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10600\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs18\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 
\par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs14\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 \hich\f1 COPYRIGHT \'a9\loch\f1  2019 S&P Global Market Intelligence, a division of S&P Global Inc. All rights reserved
\par }\pard \ltrpar\ql \li0\ri0\sl200\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 
 HYPERLINK "https://marketintelligence.spglobal.com/" }}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 spglobal.com/marketintelligence}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs14\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 \cell }\pard \ltrpar\qr \li0\ri0\sl340\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 
{\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 PAGE}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 
\hich\af1\dbch\af1\loch\f1 1}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 \cell }\pard \ltrpar
\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid4273949 \trowd \lastrow \ltrrow\ts11\trgaph108\trrh200\trleft0\trbrdrt\brdrs\brdrw10 
\trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trbrdrh\brdrs\brdrw10 \trbrdrv\brdrs\brdrw10 
\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx8000\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10600\row }\pard \ltrpar\ql \li0\ri0\sl100\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid4273949 
\par }}{\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}
{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8
\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}\ltrrow\trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph108\trrh800\trleft0\trbrdrt\brdrs\brdrw10 \trbrdrl\brdrs\brdrw10 
\trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trbrdrh\brdrs\brdrw10 \trbrdrv\brdrs\brdrw10 
\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx3500\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \lang1024\langfe1024\noproof\insrsid3346355 {\*\shppict{\pict{\*\picprop\shplid1026{\sp{\sn shapeType}{\sv 75}}{\sp{\sn fFlipH}{\sv 0}}
{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn fLayoutInCell}{\sv 1}}}\picscalex100\picscaley100\piccropl0\piccropr0\piccropt0\piccropb0\picw4198\pich1305\picwgoal2380\pichgoal740\pngblip\bliptag255{\*\blipuid 4de05a9ccfd0b11549afdb0eb59be2f2}
89504e470d0a1a0a0000000d49484452000000fb000000540802000000cb5ad6ca0000000467414d410000b18f0bfc6105000000017352474200aece1ce90000
10104944415478daed9dcd8bd3ea17c7f307641f5c4a96429662562364251702032ec20537013776212e72172e2a7795d9c5dd6465364a41a4204205a1205810
0b2245a1d231334ec797fad20183b48b2c7e3f3ac7793c3e6f4d673ae3cb3d872eee6dd3e479f93ce739e77b9e8e46bfdfcfc87e3d6bb7dbff233b0233b22c33
c87e3d0b8280e824e2897832229e88275b88781a0232229e8c8c88272323e2c9c888783232229e8cecd7247ef8f4d9e0fa7a7ef1cae713cef6ca6a7ef1ca60fd
c6eee883e6fb3bcf5fe417af6cfff5f7ec2b7ffd3d58bff169e7cddcebc5d760fdc6e0d6edd78f9f4ca7d3853a903f680fd692fcc22568c0ec56b76e7f2d0ac9
957bfdfa7cc2c92f5e39d8607d19efc21d3e9f70debd1c2c7726066bc9219b47b600f15f8be2d5e5ab6c3ab9d7e0fabac850599683eca678f1c793a735d06f3e
7ca47a0abcde9f3a3bb875bb2ccbb94ddf1d7d00d0a537d97cf88888279313ffb5283e9e3cad0731bf7089a370f8f419a6fced9973ec7fb75756a55eb60af1df
d6d85aa26ff7f0e9b3b96d1e643789783209f11bfffcfb9dec8b57debd1cc06be3de7dcc310710fbd6abcb572114f9b4f3e6fda9b3f0e6f0e9b3b9c44324c35e
b8199f4f383bcf5f68bc3bc63dbf70297fd07ef772b0f3fcc5e0da1abe09e69288279b11bf3bfac06671e39f7fc5d00562740815f047ec5b38d067d3b671e7ee
5ce2bf8c77b94fdfbd1c3094f30b97548dc66b63b07e438cecd9a7af2e5f25e2c97e207ee7f90b368bd2f87be3de7de9050ccdd1e696386d22885588c777e016
18331c836d9d0fa5d76c9d0fc59be8899f4ea7b3c4fdd66d48a3371f3e129bc7113fdadc82eb675fc96e6ab297d9e693dd842b5f5dbeba71e7ae18f511f1c744
3cf6880bf92d163f30678c3db42a26994b3c6e8f341978fdf809bb404c4f199a2c3663e98786f8d1e616dbca34e92f265e9ae80f6edd161792f4caf7a7cebe7e
fc8488ffc951cdf6ca2a76d873b778c6f7602dd9b873b74a4032dfc7efeb3f1f4f9e96af34241049efa0d43115c4e32524d5a9a4c4ab5edc52d728609ca845c4
1f5fe6ca6200e67e60ffddf8e7df8d7bf717951ab7ce872aa1662ef15f8b82e5caaa888591f1f9845345c4d4135f96257be2c793a707eb376629fb9dbb386567
23c011bf753e7cfdf809a4f86cb5bf3d738e751fcb591bf7eec3fb5fc6bb4c54c58913117f7cc47f19ef328d45254d4aeb50af1f3fe124c2c1b535a09083637b
6555241e7061afcd878fb65756351182483c1765496b5b8c3f29f1384bc1fa12ce161897b853db2babb85836dadcfa0ef77ed69e3f6833df211576f13e46c41f
1ff1a0f771e2a0b80573018fb4fcc402df2ac46b5e5be74395ff56118f570b7eb19d444abcd4dd7e7bd0fa0d2efdc59ddab8779fdf43f66f35b8b6a61ff4772f
07621788f863259ecde8e6c3474c7fe01cfff6ca2aa310839b5fb884a355f0949f76deb05d7e2665ec435085f8fce215cdd186e512cffa286e2938260177ae57
2707b76e4be3b1596df8419b6d41dcae48c4ff4ce2a5de0847f9202f4ca7d3efa0eca15c9625f3701f4f9ede79fe8291cdc9942ae2217918ac2573f5a2c1f575
a99833dadc62019234bb1589ff5a149a200a7b62d8dff4c43395094ba26c19a85e44fc7113cf405165a83f60b157766528bc3f7596c5b2d3e99479d9f7a7ce32
afcfedfe73b59ab986236f95b284afd1105f966545e261cfd113bf71e72edbd6b8b8883d175ed88910f1c7aec7ef73a0d2467079151c36a39645e72c28123360
6e211d9e78162f69ea5c3827d147354c86e7ce50704d15d371b114c0361fb83f56815e5dbe8ab7231c2f11f1c74d3cf6435297895d5dfea08ddff978f2342744
7eda7983e3545ce45f16f11853e9394dbc24e4c4a37201aba3bd3d738ecb95d9b2610b1b13cfa5a7986f90f0f1b8718dc4632e215e5dcd205b02f1988fb767ce
7127c0361f3ec272356cee65597e2f365dbc8245baaf4581b7ecadf32177de7d29c4e3ba2c57bcdc79fe024be9f8290c6e1c8cfdb063a062136e270bcc38010a
3f17671730869878bc21e0ca344e4570eea12968902d2173e574c66f1528e1e839def77142f6f6ccb9c1f5f5d9f9c76b6b6254c3e98c4b219e8b5b60358a3208
f7141cdce3e001df0a7e5382172df6fd62cd35bf7069b07e03cb442c38e46b5b7b43244ac05be743d801b8d22fc53647487c59969a6238f37f18dc9938b31f24
485f786a5f5dbe2a95350f43fc743ac53225f77a7be61ccb23d953be8c77b1fb67484da753555fb6575671408289e70ad5cc59e04ee1537a1ce5f8899004e3d4
9f883f0e75327fd0164f53c1d04b659cd96fa07ed42298db837c007f2ad5e30f433c438a6bf3cc9b5e5bfb32de65e10a7eca68738bed5d1c5283eca6583fe642
32463c942638873d584bc41e0d9f3ee3f63df839c168738b2d3f36bc9ae6911da11eff69e70de895558864876c675bf6bdfb8787f860061aebe1c3dfddd10738
065cf1faaf450163a5ff792e93807fd6f890e988272323e2c9c888783232229e8c8c88272323e2c9c888783232229e8c8c8827233b0cf1f0af8756ffa300799e
6759d6ed768fb459bd5e2f0882e217384238994cb22c1b0e87bfce9c351a8d2491fc5dce24491a8d86f87e9665cd669358ff463c58f51109c3d0308c7abd7ea4
cd6ab7db86618cc7e39f3e40e3f1d8308c5feadf13aed7ebd27f09300802e9bc1886e1380eb1fe03f19ee755b97a341ac1f5bf35f1cd66b3bacf5e22f1ed76bb
dfef1f3ff14110445144ac7f27def77dc330aa4c469224ce9efdd6c42f44f01289771c27cbb2e3279e8c273ecb32d775e7ba81b22c6ddb6e341a443c11ffdb13
df6c364dd3d4678a9d4e07ae21e2ff6ce247a3519665ad56eb4f267e329998a629cdf499f9be0ffb8086f8a2289acd6618864110d46ab546a331994c54c1f468
340231a4dbed8264c410d7100fe249afd713df6f369bb55a2d0882388ec50bdaed363cc5308c5aad96ed9b9e6615f1cd6633cf73786eabd582e7866128aa58ec
b996650541a0792eee42bd5eef743a4b21bebd67d25be5799ea669b0675114f5fbfd5eaf671886b423fd7e3f4912b838cb32957f64f308dd6130e8c3e63ccfe3
38869bc7710c6ca8628d56ab154511b479d195f98d7818474d463f1c0e59acaf22bed3e9589665db76bd5ecfb22c8a226bcfa45d751ca7dd6ee779eebaaeb16f
ec4a15f16559fabeef791eb7907abd1e3cba56aba5690a99491004f832365b8661b8ae1bec9b54e99b4b3c38ec5eaf67db36a01c0481e338800b567bd9734dd3
741c47f55ce88265596118665906edf43c4f1c840364aed2eb61f13b8e1345511cc79ee7a984bbb22c6bb51ab4278e6340c5344da9c467184677cfa03b786454
5b5c9aa68661d8b6cd2e56f9dfe17068dbb6699ab0eac2308451ad2e457c271e985609ed4992b8aecb265b1cd93ccf0dc348d394735abeef3b8ee48f003b8ed3
68346cdb0ec3505cd052e2cbb20cc3d0711ceefd7ebf6f9a66bd5ec74fc9f3dcb66ddff7c5472f25aa8141b02c2b4d53bcae1a8d866118d255a4896aa00b6118
e25b8d4623d7751dc7e196f75288ef743a8661705441e02a363e0c43cbb2b83d07168c38328081699a5c9d07ae1701eb76bbf015d6cdb22c1b8d86699a711c73
e1966559beef63008aa2f07ddfb2ac8a31b081579ee779b55a4dba8f5896c516b494f85aad1686a16a7310fb09eb58151d4989874d435c1e9ee749d36e78b4e8
8796453c4447e257a228b26d5bbac855c40741e0fbbe344a14115c0af12aad22cb32d334f11a0322c52811fc20773113bca56b5eec26c821d29624496218069e
6ed85bc481859b48e7620ef1aa58a2d56ae18e49896f369baa40cdb22c718702e25551bed8927abd6e9aa6b87975bb5d4dce0d72ead1112ff52be03ec595a922
1e56a66a5f06aaf0341f9ef8b22c5583008d811485f932154cb020399f6218866a66c1738b6849a78fbb39fcaf2a0669369b15a58e1f88075fce4526e044f150
2eaad54867da711ca95793120f8e47ea66eaf5baa67c06fe891b8865112fddd3204491d63754c44352ab6a00a492f86e87277e3299a822582832b28f606d684a
f2beef73eb41b5f5b169c5efc471ac1a46e977552e129a5d655a0d2e9f489284db91450fa4217e3c1e336982a56810d249e3e02ac4c3f2354d539abf8314d057
18b85b0ebe25c6f14b213e8e63d775f55dc00d584a5463dbb6b431f038e623a0fb8d4643d5bc300c398f23a6731ae27ddfe7827595359b4d504154a6c98c75c4
c35ac1398ae84455992ba82e2047a469ca6438cbb2a4c4abc605130fff11c731a4a1e29558ea51d91111af494317221e8e2ae96de9c4c3b6c93991c964e2380e
f6d02048e88d8b1b357b82483cd434ab4c0424be7a3b08f1cc6bb221304d93933c45e2c7e331e850d2605445bca67d3034ad568b9de101df230e2568bdc75f81
5a22f1fac0ecf07abc9478c8f6400fe9743add6e374912cbb25cd7c5513578401cd61f667845e23dcfd3abc33807d0c47e07d1e3b9d817d885ad84cb8e45e221
ff901e3986213b18f1a06de314ca344d2e28c7b2e96f4a3c14bc8f9978d836d334659ba4e779699a8a93a8d2dd97427c1445151d16e433873f402e211e563fac
3ce912148987228ba69307239e53d38ba280028d1877aa06a2d7eb49d5c9ea85bae5122f0de4207250f9d15eafc73de8f0c48fc7e3b9874a2aeea28d46836bf9
42c4434d46ea2ba1fc82b51a4dbd087eb651e5671ef2e887692352d54c243e4d53e98e33994c6cdb3e30f1aaca141ed0b22c353ba3ebba2204aeeb56dc49974b
7c18862a74541f81f7e1788de3589ad254271eb6f18a3f03c27b7e959e2e443c688eaaad8fab034061587a67cff32afe06404e3cb403ea5b52b5911b59587f9c
e39c4c265114b97b26ce4415e2a5f26a1004966561ff04923c37ca655982842f2e9b5aade6baae4ae73a3ae2410793760a04312e872bcb328e63f156100589bc
d6eb7569802755272dcbf23c2f43061515d5987b9ec78d2454b5c5dd6621e25977b88d02ce5c70fb39abc7717d57557f17201eb0e0441bbd56c34e68f57abd7e
bf0f09806559c3e1107600ce871d9878d891b92a1df8033891d2e974e0fcb365592ac9991dccc8b24c5f5b5822f14551d8b6cd38e306042afcbeefc38f2aa10b
a26cc07402289ae2a7803386a32fd8254be378688c54f108828083bb280a7034711cb7dbed66b3094bd1f77d31345a9478885ea0000f231345112816a257eaf7
fbd077364a7086aafaa1d459f7a4ed2b8aa2dfef4b37be288aa48a529ee77000038e6ab55a2d188eb22ce1801e7713cda2d4ffceb5dd6e8bba509ee750de67a7
a334716aafd7abd56a5005d3ebc130d962f14bd3fee170a892ada091aeeb4a0f748c462328a4c3b1aa5aada63a4208f711e7aedbedc2d14bdce064cfc4f68b64
c33956dff7a5e5ed56ab05e7db807595aa281d2e3cadd28f5aad16cba135778019810a866118b00f2c2625fd8fecbf67dd6ed7b66d8d4780137e7f64df89f8ff
a2d5f74c7381f43c12114ff61b13af8fe5d2345da82846c493fdea518dea9c12e421d20385443cd96f6c711c83d2d7ed76f1792cd0498220a8fe47bb8878b2df
c33a9d0ec8824c9704e9e34ffd4d37114ff65f34229e8c88272323e2c9c888783232229e8c8c88272323e2c9c888783232229e8c8c88272323e2c9c888783232229e8c88272323e2c9c8887832b23fc1fe0ffddae68623b2774b0000000049454e44ae426082}}{\nonshppict
{\pict\picscalex47\picscaley44\piccropl0\piccropr0\piccropt0\piccropb0\picw8855\pich2963\picwgoal5020\pichgoal1680\wmetafile8\bliptag255\blipupi72{\*\blipuid 4de05a9ccfd0b11549afdb0eb59be2f2}
89504e470d0a1a0a0000000d49484452000000fb000000540802000000cb5ad6ca0000000467414d410000b18f0bfc6105000000017352474200aece1ce90000
10104944415478daed9dcd8bd3ea17c7f307641f5c4a96429662562364251702032ec20537013776212e72172e2a7795d9c5dd6465364a41a4204205a1205810
0b2245a1d231334ec797fad20183b48b2c7e3f3ac7793c3e6f4d673ae3cb3d872eee6dd3e479f93ce739e77b9e8e46bfdfcfc87e3d6bb7dbff233b0233b22c33
c87e3d0b8280e824e2897832229e88275b88781a0232229e8c8c88272323e2c9c888783232229e8cecd7247ef8f4d9e0fa7a7ef1cae713cef6ca6a7ef1ca60fd
c6eee883e6fb3bcf5fe417af6cfff5f7ec2b7ffd3d58bff169e7cddcebc5d760fdc6e0d6edd78f9f4ca7d3853a903f680fd692fcc22568c0ec56b76e7f2d0ac9
957bfdfa7cc2c92f5e39d8607d19efc21d3e9f70debd1c2c7726066bc9219b47b600f15f8be2d5e5ab6c3ab9d7e0fabac850599683eca678f1c793a735d06f3e
7ca47a0abcde9f3a3bb875bb2ccbb94ddf1d7d00d0a537d97cf88888279313ffb5283e9e3cad0731bf7089a370f8f419a6fced9973ec7fb75756a55eb60af1df
d6d85aa26ff7f0e9b3b96d1e643789783209f11bfffcfb9dec8b57debd1cc06be3de7dcc310710fbd6abcb572114f9b4f3e6fda9b3f0e6f0e9b3b9c44324c35e
b8199f4f383bcf5f68bc3bc63dbf70297fd07ef772b0f3fcc5e0da1abe09e69288279b11bf3bfac06671e39f7fc5d00562740815f047ec5b38d067d3b671e7ee
5ce2bf8c77b94fdfbd1c3094f30b97548dc66b63b07e438cecd9a7af2e5f25e2c97e207ee7f90b368bd2f87be3de7de9050ccdd1e696386d22885588c777e016
18331c836d9d0fa5d76c9d0fc59be8899f4ea7b3c4fdd66d48a3371f3e129bc7113fdadc82eb675fc96e6ab297d9e693dd842b5f5dbeba71e7ae18f511f1c744
3cf6880bf92d163f30678c3db42a26994b3c6e8f341978fdf809bb404c4f199a2c3663e98786f8d1e616dbca34e92f265e9ae80f6edd161792f4caf7a7cebe7e
fc8488ffc951cdf6ca2a76d873b778c6f7602dd9b873b74a4032dfc7efeb3f1f4f9e96af34241049efa0d43115c4e32524d5a9a4c4ab5edc52d728609ca845c4
1f5fe6ca6200e67e60ffddf8e7df8d7bf717951ab7ce872aa1662ef15f8b82e5caaa888591f1f9845345c4d4135f96257be2c793a707eb376629fb9dbb386567
23c011bf753e7cfdf809a4f86cb5bf3d738e751fcb591bf7eec3fb5fc6bb4c54c58913117f7cc47f19ef328d45254d4aeb50af1f3fe124c2c1b535a09083637b
6555241e7061afcd878fb65756351182483c1765496b5b8c3f29f1384bc1fa12ce161897b853db2babb85836dadcfa0ef77ed69e3f6833df211576f13e46c41f
1ff1a0f771e2a0b80573018fb4fcc402df2ac46b5e5be74395ff56118f570b7eb19d444abcd4dd7e7bd0fa0d2efdc59ddab8779fdf43f66f35b8b6a61ff4772f
07621788f863259ecde8e6c3474c7fe01cfff6ca2aa310839b5fb884a355f0949f76deb05d7e2665ec435085f8fce215cdd186e512cffa286e2938260177ae57
2707b76e4be3b1596df8419b6d41dcae48c4ff4ce2a5de0847f9202f4ca7d3efa0eca15c9625f3701f4f9ede79fe8291cdc9942ae2217918ac2573f5a2c1f575
a99833dadc62019234bb1589ff5a149a200a7b62d8dff4c43395094ba26c19a85e44fc7113cf405165a83f60b157766528bc3f7596c5b2d3e99479d9f7a7ce32
afcfedfe73b59ab986236f95b284afd1105f966545e261cfd113bf71e72edbd6b8b8883d175ed88910f1c7aec7ef73a0d2467079151c36a39645e72c28123360
6e211d9e78162f69ea5c3827d147354c86e7ce50704d15d371b114c0361fb83f56815e5dbe8ab7231c2f11f1c74d3cf6435297895d5dfea08ddff978f2342744
7eda7983e3545ce45f16f11853e9394dbc24e4c4a37201aba3bd3d738ecb95d9b2610b1b13cfa5a7986f90f0f1b8718dc4632e215e5dcd205b02f1988fb767ce
7127c0361f3ec272356cee65597e2f365dbc8245baaf4581b7ecadf32177de7d29c4e3ba2c57bcdc79fe024be9f8290c6e1c8cfdb063a062136e270bcc38010a
3f17671730869878bc21e0ca344e4570eea12968902d2173e574c66f1528e1e839def77142f6f6ccb9c1f5f5d9f9c76b6b6254c3e98c4b219e8b5b60358a3208
f7141cdce3e001df0a7e5382172df6fd62cd35bf7069b07e03cb442c38e46b5b7b43244ac05be743d801b8d22fc53647487c59969a6238f37f18dc9938b31f24
485f786a5f5dbe2a95350f43fc743ac53225f77a7be61ccb23d953be8c77b1fb67484da753555fb6575671408289e70ad5cc59e04ee1537a1ce5f8899004e3d4
9f883f0e75327fd0164f53c1d04b659cd96fa07ed42298db837c007f2ad5e30f433c438a6bf3cc9b5e5bfb32de65e10a7eca68738bed5d1c5283eca6583fe642
32463c942638873d584bc41e0d9f3ee3f63df839c168738b2d3f36bc9ae6911da11eff69e70de895558864876c675bf6bdfb8787f860061aebe1c3dfddd10738
065cf1faaf450163a5ff792e93807fd6f890e988272323e2c9c888783232229e8c8c88272323e2c9c888783232229e8c8c8827233b0cf1f0af8756ffa300799e
6759d6ed768fb459bd5e2f0882e217384238994cb22c1b0e87bfce9c351a8d2491fc5dce24491a8d86f87e9665cd669358ff463c58f51109c3d0308c7abd7ea4
cd6ab7db86618cc7e39f3e40e3f1d8308c5feadf13aed7ebd27f09300802e9bc1886e1380eb1fe03f19ee755b97a341ac1f5bf35f1cd66b3bacf5e22f1ed76bb
dfef1f3ff14110445144ac7f27def77dc330aa4c469224ce9efdd6c42f44f01289771c27cbb2e3279e8c273ecb32d775e7ba81b22c6ddb6e341a443c11ffdb13
df6c364dd3d4678a9d4e07ae21e2ff6ce247a3519665ad56eb4f267e329998a629cdf499f9be0ffb8086f8a2289acd6618864110d46ab546a331994c54c1f468
340231a4dbed8264c410d7100fe249afd713df6f369bb55a2d0882388ec50bdaed363cc5308c5aad96ed9b9e6615f1cd6633cf73786eabd582e7866128aa58ec
b996650541a0792eee42bd5eef743a4b21bebd67d25be5799ea669b0675114f5fbfd5eaf671886b423fd7e3f4912b838cb32957f64f308dd6130e8c3e63ccfe3
38869bc7710c6ca8628d56ab154511b479d195f98d7818474d463f1c0e59acaf22bed3e9589665db76bd5ecfb22c8a226bcfa45d751ca7dd6ee779eebaaeb16f
ec4a15f16559fabeef791eb7907abd1e3cba56aba5690a99491004f832365b8661b8ae1bec9b54e99b4b3c38ec5eaf67db36a01c0481e338800b567bd9734dd3
741c47f55ce88265596118665906edf43c4f1c840364aed2eb61f13b8e1345511cc79ee7a984bbb22c6bb51ab4278e6340c5344da9c467184677cfa03b786454
5b5c9aa68661d8b6cd2e56f9dfe17068dbb6699ab0eac2308451ad2e457c271e985609ed4992b8aecb265b1cd93ccf0dc348d394735abeef3b8ee48f003b8ed3
68346cdb0ec3505cd052e2cbb20cc3d0711ceefd7ebf6f9a66bd5ec74fc9f3dcb66ddff7c5472f25aa8141b02c2b4d53bcae1a8d866118d255a4896aa00b6118
e25b8d4623d7751dc7e196f75288ef743a8661705441e02a363e0c43cbb2b83d07168c38328081699a5c9d07ae1701eb76bbf015d6cdb22c1b8d86699a711c73
e1966559beef63008aa2f07ddfb2ac8a31b081579ee779b55a4dba8f5896c516b494f85aad1686a16a7310fb09eb58151d4989874d435c1e9ee749d36e78b4e8
8796453c4447e257a228b26d5bbac855c40741e0fbbe344a14115c0af12aad22cb32d334f11a0322c52811fc20773113bca56b5eec26c821d29624496218069e
6ed85bc481859b48e7620ef1aa58a2d56ae18e49896f369baa40cdb22c718702e25551bed8927abd6e9aa6b87975bb5d4dce0d72ead1112ff52be03ec595a922
1e56a66a5f06aaf0341f9ef8b22c5583008d811485f932154cb020399f6218866a66c1738b6849a78fbb39fcaf2a0669369b15a58e1f88075fce4526e044f150
2eaad54867da711ca95793120f8e47ea66eaf5baa67c06fe891b8865112fddd3204491d63754c44352ab6a00a492f86e87277e3299a822582832b28f606d684a
f2beef73eb41b5f5b169c5efc471ac1a46e977552e129a5d655a0d2e9f489284db91450fa4217e3c1e336982a56810d249e3e02ac4c3f2354d539abf8314d057
18b85b0ebe25c6f14b213e8e63d775f55dc00d584a5463dbb6b431f038e623a0fb8d4643d5bc300c398f23a6731ae27ddfe7827595359b4d504154a6c98c75c4
c35ac1398ae84455992ba82e2047a469ca6438cbb2a4c4abc605130fff11c731a4a1e29558ea51d91111af494317221e8e2ae96de9c4c3b6c93991c964e2380e
f6d02048e88d8b1b357b82483cd434ab4c0424be7a3b08f1cc6bb221304d93933c45e2c7e331e850d2605445bca67d3034ad568b9de101df230e2568bdc75f81
5a22f1fac0ecf07abc9478c8f6400fe9743add6e374912cbb25cd7c5513578401cd61f667845e23dcfd3abc33807d0c47e07d1e3b9d817d885ad84cb8e45e221
ff901e3986213b18f1a06de314ca344d2e28c7b2e96f4a3c14bc8f9978d836d334659ba4e779699a8a93a8d2dd97427c1445151d16e433873f402e211e563fac
3ce912148987228ba69307239e53d38ba280028d1877aa06a2d7eb49d5c9ea85bae5122f0de4207250f9d15eafc73de8f0c48fc7e3b9874a2aeea28d46836bf9
42c4434d46ea2ba1fc82b51a4dbd087eb651e5671ef2e887692352d54c243e4d53e98e33994c6cdb3e30f1aaca141ed0b22c353ba3ebba2204aeeb56dc49974b
7c18862a74541f81f7e1788de3589ad254271eb6f18a3f03c27b7e959e2e443c688eaaad8fab034061587a67cff32afe06404e3cb403ea5b52b5911b59587f9c
e39c4c265114b97b26ce4415e2a5f26a1004966561ff04923c37ca655982842f2e9b5aade6baae4ae73a3ae2410793760a04312e872bcb328e63f156100589bc
d6eb7569802755272dcbf23c2f43061515d5987b9ec78d2454b5c5dd6621e25977b88d02ce5c70fb39abc7717d57557f17201eb0e0441bbd56c34e68f57abd7e
bf0f09806559c3e1107600ce871d9878d891b92a1df8033891d2e974e0fcb365592ac9991dccc8b24c5f5b5822f14551d8b6cd38e306042afcbeefc38f2aa10b
a26cc07402289ae2a7803386a32fd8254be378688c54f108828083bb280a7034711cb7dbed66b3094bd1f77d31345a9478885ea0000f231345112816a257eaf7
fbd077364a7086aafaa1d459f7a4ed2b8aa2dfef4b37be288aa48a529ee77000038e6ab55a2d188eb22ce1801e7713cda2d4ffceb5dd6e8bba509ee750de67a7
a334716aafd7abd56a5005d3ebc130d962f14bd3fee170a892ada091aeeb4a0f748c462328a4c3b1aa5aada63a4208f711e7aedbedc2d14bdce064cfc4f68b64
c33956dff7a5e5ed56ab05e7db807595aa281d2e3cadd28f5aad16cba135778019810a866118b00f2c2625fd8fecbf67dd6ed7b66d8d4780137e7f64df89f8ff
a2d5f74c7381f43c12114ff61b13af8fe5d2345da82846c493fdea518dea9c12e421d20385443cd96f6c711c83d2d7ed76f1792cd0498220a8fe47bb8878b2df
c33a9d0ec8824c9704e9e34ffd4d37114ff65f34229e8c88272323e2c9c888783232229e8c8c88272323e2c9c888783232229e8c8c88272323e2c9c888783232229e8c88272323e2c9c8887832b23fc1fe0ffddae68623b2774b0000000049454e44ae426082}}}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid10976062 
\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid10976062 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph108\trrh800\trleft0\trbrdrt\brdrs\brdrw10 \trbrdrl
\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trbrdrh\brdrs\brdrw10 \trbrdrv\brdrs\brdrw10 
\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx3500\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid10976062 
\par }\pard \ltrpar\ql \li0\ri0\sl300\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs46\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 
Alexion Pharmaceuticals, Inc. NasdaqGS:ALXN}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid10976062 
\par }\pard \ltrpar\ql \li0\ri0\sl280\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs60\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 Special Call}{\rtlch\fcs1 
\af1 \ltrch\fcs0 \b\fs60\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 
\par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs36\cf20\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 Thursday, March 15, 2018 12:30 PM GMT\page }{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs36\cf20\loch\af1\hich\af1\dbch\af1\insrsid10976062 
\par \ltrrow}\trowd \irow0\irowband0\ltrrow\ts11\trgaph108\trleft0\trftsWidth2\trwWidth5000\trftsWidthB3\trftsWidthA1\trautofit1\trpaddl108\trpaddt20\trpaddb100\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband
\tblind0\tblindtype3 \clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx7000\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx7500\pard \ltrpar\ql \li0\ri0\sl260\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\b\fs50\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 Table of Contents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs36\cf20\loch\af1\hich\af1\dbch\af1\insrsid10976062 
\par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs50\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf20\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1  }{\rtlch\fcs1 \af1 \ltrch\fcs0 
\b\fs50\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs50\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 
\trowd \irow0\irowband0\ltrrow\ts11\trgaph108\trleft0\trftsWidth2\trwWidth5000\trftsWidthB3\trftsWidthA1\trautofit1\trpaddl108\trpaddt20\trpaddb100\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband
\tblind0\tblindtype3 \clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx7000\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx7500\row \ltrrow}\trowd \irow1\irowband1\ltrrow
\ts11\trgaph108\trleft0\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddt20\trpaddb100\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalc\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx4200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx10200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10900\pard \ltrpar\ql \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 
 HYPERLINK \\l "0" }{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000200000030000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 Call Participants}}}\sectd \ltrsect\linex0\headery400\footery400\colsx708\endnhere\titlepg\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 
\b\fs18\cf20\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\qc \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 ........................................................................................................................................................}{\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\qr \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 
\hich\af1\dbch\af1\loch\f1 3}{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \trowd \irow1\irowband1\ltrrow
\ts11\trgaph108\trleft0\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddt20\trpaddb100\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalc\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx4200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx10200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10900\row \ltrrow}\pard \ltrpar\ql \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 
\hich\af1\dbch\af1\loch\f1  HYPERLINK \\l "1" }{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000200000031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 Presentation}}}\sectd \ltrsect\linex0\headery400\footery400\colsx708\endnhere\titlepg\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\qc \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 
........................................................................................................................................................}{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell 
}\pard \ltrpar\qr \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 4}{\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 
\trowd \irow2\irowband2\ltrrow\ts11\trgaph108\trleft0\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddt20\trpaddb100\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 
\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx4200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx10200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10900\row \ltrrow}\pard \ltrpar\ql \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 
\hich\af1\dbch\af1\loch\f1  H\hich\af1\dbch\af1\loch\f1 YPERLINK \\l "2" }{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000200000032000000}}}{\fldrslt {
\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 Question and Answer}}}\sectd \ltrsect\linex0\headery400\footery400\colsx708\endnhere\titlepg\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 
\af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\qc \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 ........................................................................................................................................................}{\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\qr \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 
\hich\af1\dbch\af1\loch\f1 8}{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \trowd \irow3\irowband3\lastrow \ltrrow
\ts11\trgaph108\trleft0\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddt20\trpaddb100\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalc\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx4200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx10200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10900\row }\pard \ltrpar\ql \li0\ri0\sl280\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs36\cf20\loch\af1\hich\af1\dbch\af1\insrsid10976062 \sect }\sectd \ltrsect
\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 \hich\af1\dbch\af1\loch\f1 ALEXION PHARMACEUTICALS, INC.  SPECIAL CALL   |    MAR 15, 2018}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \insrsid4273949 
\par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 
\par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid3346355 {\shp{\*\shpinst\shpleft0\shptop0\shpright10656\shpbottom0\shpfhdr0\shpbxcolumn\shpbxignore\shpbypara\shpbyignore\shpwr3\shpwrk0\shpfblwtxt0\shpz0\shplid2051
{\sp{\sn shapeType}{\sv 20}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn fFillOK}{\sv 0}}{\sp{\sn fNoFillHitTest}{\sv 0}}{\sp{\sn lineWidth}{\sv 12700}}
{\sp{\sn dhgt}{\sv 251657216}}{\sp{\sn fEditedWrap}{\sv 0}}{\sp{\sn fBehindDocument}{\sv 0}}{\sp{\sn fIsButton}{\sv 0}}{\sp{\sn fPseudoInline}{\sv 0}}{\sp{\sn fLayoutInCell}{\sv 1}}}{\shprslt{\*\do\dobxcolumn\dobypara\dodhgt8192
\dpline\dpptx0\dppty0\dpptx10656\dppty0\dpx0\dpy0\dpxsize10656\dpysize0\dplinew20\dplinecor0\dplinecog0\dplinecob0}}}}{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf1\loch\af1\hich\af1\dbch\af1\insrsid4273949 
\par }}{\footerr \ltrpar \ltrrow\trowd \ltrrow\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt
\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 
\ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid4273949 \cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid4273949 \trowd \ltrrow
\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \ltrrow
\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\pard\plain \ltrpar
\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf21\insrsid4273949 COPYRIGHT \'a9
 2019 S&P Global Market Intelligence, a division of S&P Global Inc. All rights reserved.\cell }\pard \ltrpar\s15\qr \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid4273949 
PAGE}}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid4273949 3}}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid4273949 \cell 
}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs18\cf21\insrsid4273949 \trowd \ltrrow\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt
\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \lastrow \ltrrow
\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid4273949 HYPERLINK "http://www.marketintelligence.sglobal.com" }}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf21\insrsid4273949 spglobal.com/marketintelligence }}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid4273949 \cell }\pard\plain \ltrpar
\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid4273949 
\trowd \lastrow \ltrrow\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row }\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f40\fs16\insrsid4273949 
\par }}\ltrrow\trowd \irow0\irowband0\ltrrow\ts11\trrh-1\trleft0\trftsWidth3\trwWidth10640\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f40\fs16\insrsid4273949 {\*\bkmkstart 0}{\*\bkmkend 0}\cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 
\rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f40\fs16\insrsid4273949 \trowd \irow0\irowband0\ltrrow
\ts11\trrh-1\trleft0\trftsWidth3\trwWidth10640\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \irow1\irowband1\ltrrow
\ts11\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 
{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs48\cf1\insrsid4273949 Call Participants}{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f40\fs48\cf1\insrsid4273949 \cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 
\rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f40\fs48\cf1\insrsid4273949 \trowd \irow1\irowband1\ltrrow
\ts11\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \irow2\irowband2\lastrow \ltrrow
\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth3547\clcbpatraw8 \cellx3547\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth3547\clcbpatraw8 \cellx7094\clvertalt\clbrdrt
\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth3547\clcbpatraw8 \cellx10641\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 
\ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid4273949 EXECUTIVES}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs14\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Elena H. Ridloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 
Former Vice President of Investor Relations}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line  
\line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid4273949 ANALYSTS}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Anupam Rama}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 JP Morgan Chase & Co, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Carlos Efrain Solorzano-Say}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Deutsche Bank AG, Research Division}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Christopher Joseph Raymond}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid4273949 Piper Jaffray Companies, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Eric Thomas Schmidt}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Cowen and Company, LLC, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Evan David Seigerman}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Barclays Bank PLC, Research Division}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Geoffrey Craig Porges}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid4273949 SVB Leerink LLC, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Kennen B. MacKay}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 RBC Capital Markets, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 Laura Kathryn Chico}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Raymond James & Associates, Inc., Research Division}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line \cell  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Robyn  Karnauskas}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid4273949 Citigroup Inc, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Terence C. Flynn}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Goldman Sachs Group Inc., Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 Vikram  Purohit}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Morgan Stanley, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs14\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Yatin  Suneja}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 
SunTrust Robinson Humphrey, Inc., Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Ying Huang}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs14\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 BofA Merrill Lynch, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949  \line \cell \cell }\pard\plain \ltrpar
\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid4273949 
\trowd \irow2\irowband2\lastrow \ltrrow\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone 
\clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth3547\clcbpatraw8 \cellx3547\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth3\clwWidth3547\clcbpatraw8 \cellx7094\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth3547\clcbpatraw8 \cellx10641\row }\pard \ltrpar
\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid4273949 \sect }\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\footerr 
\ltrpar \ltrrow\trowd \ltrrow\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid4273949 \cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid4273949 \trowd \ltrrow
\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \ltrrow
\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\pard\plain \ltrpar
\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf21\insrsid4273949 COPYRIGHT \'a9
 2019 S&P Global Market Intelligence, a division of S&P Global Inc. All rights reserved.\cell }\pard \ltrpar\s15\qr \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid4273949 
PAGE}}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid4273949 7}}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid4273949 \cell 
}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs18\cf21\insrsid4273949 \trowd \ltrrow\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt
\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \lastrow \ltrrow
\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid4273949 HYPERLINK "http://www.marketintelligence.sglobal.com" }}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf21\insrsid4273949 spglobal.com/marketintelligence }}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid4273949 \cell }\pard\plain \ltrpar
\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid4273949 
\trowd \lastrow \ltrrow\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row }\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f40\fs16\insrsid4273949 
\par }}\ltrrow\trowd \irow0\irowband0\lastrow \ltrrow\ts11\trrh-1\trleft0\trftsWidth3\trwWidth10640\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb
\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949 {\*\bkmkstart 1}{\*\bkmkend 1}\cell }\pard\plain \ltrpar
\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949 
\trowd \irow0\irowband0\lastrow \ltrrow\ts11\trrh-1\trleft0\trftsWidth3\trwWidth10640\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row }\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs48\cf1\insrsid4273949 Presentation}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Good morning, and welcome to the Alexion conference call to discuss the ALXN1210 Phase III study results. Today's call is being recorded. For opening remarks and introductions, I would now like to turn the call over to Elena Ridloff,
 Vice President, Investor Relations. Please go ahead, ma'am. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Elena H. Ridloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Former Vice President of Investor Relations}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid4273949 Thank you, and good morning, and thank you for joining us today -- on today's call to discuss the top line results from the Phase III study of ALXN1210 in complement inhibitor treatment-na\'ef
ve patients with PNH. Today's call will be led by our CEO, Ludwig Hantson; and John Orloff, our Global Head of R&D. Ludwig and John will be joined by Paul Clancy, our Chief Financial Officer; 
and Lori Shafner, the Global Development Team Lead for ALXN1210 for Q&A. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
You can access the webcast slides that will be presented on this call by going to the Events section of our Investor Relations page on our website. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Before we begin, I would 
like to point out that we will be making forward-looking statements regarding ALXN1210 and the company's plans for 1210. And these statements involve certain risks and uncertainties that could cause our actual results to differ materially. Please take a l
ook at the risk factors discussed in our SEC filings for additional details. These forward-looking statements apply only as of today, and we undertake no duty to update any of these statements after the call. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Thank you. Now I'll turn the call over to Ludwig. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Thank you, Elena, and thanks to everyone for joining us this morning. I'm very pleased to report that the 1210 Phase III trial in complement inhibitor treatment-na\'efve patients with PNH was a success. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Th
is is a foundational study as the first and only Phase III head-to-head study versus Soliris, the current standard of care. 1210 met the high hurdle of meeting non-inferiority for both co-primary endpoints as well as all 4 key secondary endpoints as we ai
m to establish 1210 as the new standard of care for PNH. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Before we get into the data, I'd like to recognize the many patients, their families and health care providers who participated in the trial as well as our dedicated employees of Alexion. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  
\line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 No
w to the results and starting with Slide 4. This pivotal study was conducted globally in 246 patients with PNH who had never been treated with a complement inhibitor. Treatment with 1210 met the study objective of achieving non-inferiority to Soliris on b
oth of the co-primary endpoints of transfusion avoidance and LDH normalization through 26 weeks of treatment. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
1210 also demonstrated non-inferiority across all 4 key secondary endpoints, including breakthrough hemolysis. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
In addition, numeric resul
ts favoring 1210 were observed for all 6 endpoints. 1210 was well tolerated, with a safety profile consistent with that seen for Soliris. Having a new treatment that provides immediate, complete and sustained C5 inhibition when administered every 8 weeks 
could be a meaningful improvement for patients with PNH who currently need infusions every 2 weeks. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
This would reduce the number of annual infusions for patients from approximately 26 times per year with Soliris to only 6 times per year with 1210. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Turning to the results for the co-primary endpoints on Slide 5. In addition to achieving non-inferiority on both co-primary endpoints, the numeric results favored 1210. 74% of patients receiving 1210 achieved transfusion avoidance versus 66% of patients o
n Soliris. The modeled estimate of LDH normalization to 26 weeks was 54% for patient receiving 1210 versus 49% of Soliris patients. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid4273949 Moving to Slide 6. The study met non-inferiority for its 4 key secondary endpoints. In addition, as you see here, numeric results in favor of 1210 were observed for all of these endpoints. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Once again, I'm very pleased with these results. Meeting the high threshold in the study reinforces our ambition to establish 1210 as a new standard of care for patients with PNH. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 With that, I'll turn the call over to John. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 
John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Thank you, Ludwig. It is a great pleasure to speak with you today about the results from our Phase III study of ALXN1210 in treatment-na\'efve patients with PNH. \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
This is an exciting day for the PNH community and for the many people at Alexion who have worked tirelessly to deliver these results for patients with PNH. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Turning to Slide 8. As a brief refresher, 1210 is an innovative, lo
ng-acting C5 inhibitor discovered and developed by Alexion. It delivers immediate, complete and sustained reduction of free C5 activity and has a terminal half-life of approximately 42 days. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Turning to the study design on Slide 9. This is a Phase III 
open label, randomized, active-controlled, multicenter global study to evaluate the safety and efficacy of 1210 versus Soliris in adult patients with PNH who are na\'ef
ve to complement inhibitor treatment at enrollment. The study was designed to demonstrate non-inferiority and enrolled 246 patients who were randomized in a 1:1 ratio to receive 1210 or Soliris. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 The study consisted of a 4-week screening period, a 26-week randomized treatment period and an extension study in which patients are receiving 1210
 for up to 2 years or until regulatory approval is obtained. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Patients in the 1210 arm were treated in 3 weight-based dosing cohorts every 8 weeks after induction dosing. Patients in the Soliris arm were treated every 2 weeks after induction, in accordance with the labeled dosing regimen for Soliris in PNH. \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Moving to Slide 10. The 2 study arms were well balanced with regard to baseline characteristics. The mean LDH levels at baseline were approximately 1,600 units per liter for each study arm, with
 approximately 86% of 1210 and 87% of Soliris-treated patients having an LDH greater than 3x the upper limit of normal at baseline. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid4273949 In addition, approximately 82% of patients in each arm had a history of transfusions in the prior year, with 18% of patients in each arm having received over 14 units of packed red blood cells in the prior year. \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Enrollment of patients without a history of transfusion in the past year was 18% in the 1210 arm and 17% in the Soliris arm. 
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 This was a global study conducted in 25 countries with a diverse set of patients representative of the na\'ef
ve population with active disease that allowed us to make direct comparisons between ALXN1210 and Soliris. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
As noted by Ludwig and shown on Slide 11, having co-primary endpoi
nts set a high hurdle for success. This is the first and only study in which transfusion avoidance and hemolysis, as directly measured by normalization of LDH levels, were both prospectively assessed. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 In addition, 4 key secondary endpoints were assess
ed. The percentage change in LDH from baseline to Day 183, change in quality of life assessed via the FACIT-Fatigue scale from baseline to Day 183, the proportion of patients with breakthrough hemolysis and the proportion of patients with stabilized hemog
lobin from baseline through Day 183. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Let me orient you to the plots on Slide 12. The lines represent the lower and upper bounds of the 95% confidence intervals for the difference in the treatment effect estimates. They were assessed relative to the res
pective predefined non-inferiority thresholds in red. For transfusion avoidance, the lower bound of the 95% confidence interval is minus 4.7%, which is greater than the predefined non-inferiority threshold of minus 20%. \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 For LDH normalization, which is
 assessed by an odds ratio, the lower bound of the 95% confidence interval is 0.8, which is greater than the predefined non-inferiority threshold of 0.39. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 You also see that the 95% confidence intervals for both endpoints fall more to the right side of the chart, indicating that numeric results favored 1210 versus Soliris. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Here on Slide 13, we have these same plots for the key secondary endpoints. As you see, all 4 met non-inferiority as the lower bounds of the 95% confidence intervals are greater than the predefined non-inferiority thresholds. \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 In addition, the point estimates for the relative treatment effect favored 1210 over Soliris for all 4 endpoints. \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Since we achieved non-inferiority across both co-primary in all 4 key secondary endp
oints, our statistical analysis plan allowed us to test for superiority. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
The hierarchical testing order pre-specified breakthrough hemolysis as the first endpoint tested for superiority. The percentage of patients with breakthrough hemolysis was 4% in
 1210, and 10.7% on Soliris, with a P value of 0.074, which did not achieve statistical superiority. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
I'd like to point out that this is the first and only Phase III PNH study to prospectively evaluate breakthrough hemolysis and with a rigorous and obj
ective clinical definition agreed to with health authorities. Breakthrough hemolysis occurs when LDH levels rise to above 2x the upper limit of normal after being below 1.5x the upper limit of normal, along with a sign or symptom associated with PNH. 
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
We believe this is a true indicator of the return of symptomatic disease and poses a risk to patients. These results support the hypothesis that immediate, complete and sustained terminal complement inhibition by maintaining a trough drug exposure suffici
ent to inhibit terminal complement activity over the entire dosing interval as 1210 was specifically designed to achieve may be important in minimizing the risk of breakthrough hemolysis. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  
\line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Here on Slide 14, this chart shows mean LDH levels at each time 
point assessed. You see that for 1210, the mean LDH was reduced to approximately the upper limit of normal by Day 22 and maintained through the duration of the study. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Turning to Slide 15. You see that in the study, 1210 had a safety profile consistent with that seen for Soliris. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
1210 was generally well tolerated, and there were no reported cases of meningococcal infections in either arm of the study. Treatment compliance was 100% for 1210 and 99.95% for Soliris. No immunogenicity issues were obser
ved. One treatment-emergent antidrug antibody was observed in each arm with no apparent effects on PK/PD, efficacy or safety. No neutralizing antibodies were observed. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 To summarize, we're very pleased with the data from this Phase III study that established non-inferiority across the co-primary and all 4 key secondary endpoints with numeric results favoring 1210. 
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
In addition, an extended dosing interval of 8 weeks could be a meaningful improvement for patients and their treating physicians. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid4273949 I'll now turn the call back to Ludwig. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Thank you, John. And let me conclude today's call by reiterating how pleased we are with these successful results. Our goal is to establish 1210 as the new standard of care bas
ed on the efficacy and safety profile established in our pivotal study and immediate, complete and sustained C5 inhibition over an 8-week dosing interval. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 These results speak to our leadership in complement and commitment to improving the lives of pat
ients with devastated complement-mediated diseases. I'm very proud of our cross-functional team that has rapidly driven 1210 from research to pivotal Phase III trial completion. Through innovation, expedited global development and leadership, they continu
e to strive to raise the bar for patients. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
We look forward to updating you when we have additional data readouts from 1210 from our large global PNH SWITCH study in Q2 and our third Phase III readout from our pivotal aHUS study in Q4. In addition, we'r
e on track to complete our regulatory filings for PNH in U.S., Europe and Japan in the second half of 2018. \line We will now open the call to questions. Operator? \line \sect }\sectd \ltrsect
\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\footerr \ltrpar \ltrrow\trowd \ltrrow
\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid4273949 \cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid4273949 \trowd \ltrrow
\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \ltrrow
\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\pard\plain \ltrpar
\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf21\insrsid4273949 COPYRIGHT \'a9
 2019 S&P Global Market Intelligence, a division of S&P Global Inc. All rights reserved.\cell }\pard \ltrpar\s15\qr \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid4273949 
PAGE}}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid4273949 17}}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid4273949 \cell 
}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs18\cf21\insrsid4273949 \trowd \ltrrow\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt
\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \lastrow \ltrrow
\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid4273949 HYPERLINK "http://www.marketintelligence.sglobal.com" }}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf21\insrsid4273949 spglobal.com/marketintelligence }}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid4273949 \cell }\pard\plain \ltrpar
\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid4273949 
\trowd \lastrow \ltrrow\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row }\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
\par }}\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line 
{\*\bkmkstart 2}{\*\bkmkend 2}
\par }\pard \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs48\cf1\insrsid4273949 Question and Answer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 [Operator Instructions] Our first question comes from t
he line of Eric Schmidt of Cowen and Company. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Eric Thomas Schmidt}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Cowen and Company, LLC, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid4273949 Congrats on the results. I assume all these datasets will be included on the eventual label showing the trends and superiority for ALXN1210
, you can correct me if I'm wrong on that. But I could also imagine you guys would like to have a claim of superiority, and given you just missed here with the primary endpoint, are you thinking about another trial that is either better powered to show su
periority on this endpoint, or maybe superiority in 1 of the other 6 endpoints? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Eric, this is John. Thanks for the question. First of all, I think we're very proud of the study results 
here. I think they're very solid across the board with robust results across all 6 endpoints showing non-inferiority and numerical trends in favor of 1210. We will be proceeding with regulatory filings in the second half of this year, that includes the U.
S
., the EU and Japan. Any labeling discussions, I think, are premature. We certainly will be submitting the entire dataset that will include the 301 study as well as the readout of the 302 study that's expected in the second quarter. And of course, the bre
a
kthrough hemolysis results, we think, are also clinically meaningful and important with a twofold difference in rates that barely missed statistical significance. And I'll remind you that this is the first prospectively defined study looking at breakthrou
g
h hemolysis using rigorous criteria that includes an objective assessment of LDH as well as a clinical sign or symptom of intravascular hemolysis. So certainly, the assumptions were different than what have been clinically reported with respect to breakth
r
ough hemolysis. And the rates seen with Soliris were actually lower than what's previously been reported, in the 20% to 25% range. We found only 11%. So even with that high bar and that low rate of hemolysis, we were able to show roughly a twofold lower r
ate in the 1210 arm. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Yes. Our objective will be to have the full dataset reflected in the clinical trial section. Of course, that's up to the regulators to decide. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 Eric Thomas Schmidt}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Cowen and Company, LLC, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Thoughts on another study? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 We're going to analyze these data. These are top line results. We think they're very robust and clinically meaningful. And right now, we'
re analyzing the rest of the results. And our plans for any additional studies, we'll share with you later this year. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Yes. As we -- in the next weeks and months, as we're gearing up for submission, we will be talki
ng with the regulators. And we might get additional insights on how they look at this data set, and that will help us to decide which direction that we will be taking. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Our next question is from Anupam Rama of JPMorgan. 
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Elena H. Ridloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid4273949 Former Vice President of Investor Relations}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Anupam? I think you're on mute, Anupam. Operator, let's go to the next question. We'll try to get back to Anupam. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 
Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Anupam Rama, your line is open. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Anupam Rama}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 JP Morgan Chase & Co, Research Division}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Hello, can you hear me? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 Elena H. Ridloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Former Vice President of Investor Relations}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Yes, we can hear you now. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 Anupam Rama}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 JP Morgan Chase & Co, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Wondering what endpoints and analyses we should be expect
ing at a medical meeting that were presented beyond the top line results today that could help us better understand the overall clinical profile of 1210? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 So we're sharing today the top
 line results. We still have some analysis that's ongoing. That would be included in any medical congress that may be submitted sometime in the second quarter. And so we'll go into more details of those results, including the secondary endpoints and the P
K/PD analysis. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Our next question is from Terence Flynn. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Terence C. Flynn}{\rtlch\fcs1 
\af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Goldman Sachs Group Inc., Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Maybe just you could help frame for us, as you think about your initial commercialization strategy here given the 
profile you've seen, maybe just walk us through the value proposition now that you've seen the top line data? And maybe would that differ across geography, or do you see that pretty consistent now given the data that we saw today? \line }{\rtlch\fcs1 
\af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Yes. Thanks for the question. And as John was saying, and as I've said before, we're really pleased with the results. And I'm really proud of what the 1210 team did. So well done. So the -- I believe that we have a strong 1210 clinical pro
file and that we have strong potential points of differentiation and that we're building a strong case for a potential facilitated conversion from Soliris to 1210. And this organization has a decade of experience dealing with PNH, so our employees underst
a
nd the patient insights and the patient journeys. And when you think about where we are, first of all, 1210, 6 infusions per year versus 26 infusions per year for Soliris. From a patient perspective, that is a very important change. In talking to patients
,
 they have to go to the hospital every 2 weeks. It's almost like a full month of days in the year that you have to dedicate to driving to the hospital, getting the infusion, getting back and so on. So this is a big deal and that's what we hear from our pa
t
ients. The second thing is, as John was saying, we see numeric trends in favor of 1210. And we're really pleased to see a very low percentage of breakthrough hemolysis rates of 4%. We believe that is clinically relevant, and we believe that that's going t
o
 be a focus of discussion in the medical community. You know that this is a topic that is well discussed but has never been prospectively measured. And to come up with a definition that was agreed with the regulators and come up with results that are real
l
y low, low single digits, that's pretty impressive. Plus, we also have a subcu development that's moving into Phase III, and you know that we're going to have this bridging approach from subcu to IV. And the subcu option could be another potential point o
f
 differentiation. So what I'm trying to say is, I think we're building a strong case for conversion from Soliris to 1210. So I'm really pleased with where we are. Is there going to be a geographical difference in how we approach the markets? I think we're
 
going to -- clearly, in the next month, we will have the 302 data, so we'll have the full 1210 dataset in making sure that we do the right thing for patients and the organization. So we'll keep you posted on what it means, but I believe that we're in a pr
etty good situation here. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Our next question is from Matthew Harrison of Morgan Stanley. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 Vikram  Purohit}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Morgan Stanley, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 This is Vikram on for Matthew. So our question is about the upcoming data from the SWITCH stu
dy. What key differences would you highlight between the study that read out today and the SWITCH study, so that we can think about how today's data influences what could be the readout from that upcoming study? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 
Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Yes, I think, the key difference is that these are eculizumab experienced PNH patients. So they all have been on a stable dose -- stable course of disease for eculizumab. And one point regarding breakthrough hemolysis is that al
l these patients, it was a requirement coming into this study that they had no evidence of breakthrough for the 6 months prior to entry. So we anticipate the rates of breakthrough hemolysis to be even lower in the SWITCH study than what we saw in the na
\'efve
 study. Although we're going to be analyzing for breakthrough, we, again, think that percentages will be low. The primary endpoint is percent change in LDH, which is a modeled-based approach to LDH with a non-inferiority margin. About 200 patients, 197, w
ere enrolled. And again, we're anticipating that we'll have results in the second quarter, the study being about 5 to 6 weeks behind the 301 study. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 So 301 is our pivotal study. And that was agreed on with the regula
tors. 302 is a supportive study. So -- and when you think about the data that we're presenting today, I believe we have a very strong regulatory pathway forward. So we're really pleased. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  
\line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Our next question is from Geoffrey Porges of Leerink. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Geoffrey Craig Porges}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 SVB Leerink LLC, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid4273949 Just to follow up on the question about the SWITCH study. Could you tell us what the hierarchy for assessing superiority is in the SWITCH study? And just on a related note, could you also 
confirm where you are in terms of the number of [ mening ] cases, septicemia cases that you've observed in the post-marking experience? Obviously, great results here on safety, but could you just give us that update? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 
Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
So Geoff, we haven't disclosed the hierarchy, as we did not for 301. But we are looking at, basically, all the same endpoints. The primary endpoint, as we said, was percentage change in LDH -- non-inferiority design. So the
 study is also non-inferiority for that and the secondary endpoints. And we'll go ahead and test for superiority in a hierarchical way. And the second part of the question related... \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line 
 \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Meningococcal. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Meningococcal infections, we still have 3 cases, as we've disclosed previously. We have over 200 patient years of exposure. The rates calculate to consistent rates relative to Soliris in the clinical 
program. And there were no cases of meningococcal infection in the 301 study or the extension thus far in either arm. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 So 3 cases for the entire 1210 dataset. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 
John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Right. That comes from the Phase Ib and Phase II studies, not in the 301 study. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 And then 301 0, 302 0 and extension study 0. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 
John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Right. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Our next question is from Robyn Karnauskas of Citigroup. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 
\af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Robyn  Karnauskas}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Citigroup Inc, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 A quick question on the core responders, the core responding markets. Can you give us any sense of [ whether ] any o
f those patients in your [ SWITCH ] study and [indiscernible] Doctors using [indiscernible] switching from proof of switch from the core responders to 1210? Can you get a better feel of more confidence in treating these hard to treat patients? And then, s
econd would be just a follow-up on the patents given the progression that you [indiscernible]. Any updated thoughts on when we could hear about [indiscernible] patent for PNH? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line 
}{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 I'll start with the second question. So
 on the patent, so no new update. As you know, we got the new patents in U.S. till 2027. So composition of matter, method of use and formulation. We also got Japan, as you know, 2027. And in Europe, we continue to have an open dialogue. And you should hea
r back from us in 2018, but we're taking a very similar approach to our successful approach in U.S. and Japan. And we believe that we have a very strong case. And with respect to the first question? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 
Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Yes, I guess, with respect to responders, first of all, eculizumab is really -- Soliris has really established a high bar in patients with PNH. I talked about breakthrough hemolysis, the rates being much lower as we've assessed it in a prospe
ctive and rigorous manner than perhaps what has been reported clinically. In addition to that, LDH comes down to close to the upper limit of normal, ranging between 1.0 and 1.3; and for 1210, 1.0 to 1.1 across the 6 months of the study. So it's really a h
i
gh bar. And we've taken that to another level, we think, by looking at co-primary endpoints that have clinical relevance, transfusion avoidance and LDH normalization. And we do think that there is differentiation with 1210, despite the high bar that eculi
zumab, Soliris has established with non-inferiority across the 6 endpoints, but also numerical favorability for 1210. And the consistency for all those endpoints, we think, is very robust in 1210's favor. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 
CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Soliris ha
s set a high bar. And one other thing that we're really pleased with is the great LDH results. And the mean LDH values were between 1.0 and 1.1 from month 1 to month 6 for 1210, which is a very strong reduction and a consistent effect across the patient p
opulation. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Robyn  Karnauskas}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Citigroup Inc, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Yes, but for core responders, though, do you think that patients -- or doctors need more data, specifically in that population, regarding high doses? Or like in that unique population, w
hat have you heard from your market research on what the doctors wanted or the patients want? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Yes. Well -- so certainly, we'll have data from the SWITCH study that will allow us to pot
entially answer that question with data, so patients who have been on eculizumab in the past and then come in and are randomized to receive 1210 or eculizumab. So we will have that SWITCH experience that will be supportive of the na\'ef
ve population. And all of the patients that were on Soliris have switched to 1210 in the extension study of 301 as well, which gives us additional data in terms of their experience of 1210 relative to eculizumab. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Our next question is from Ying Huang of Bank of America Merrill Lynch. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Ying Huang}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 BofA Merrill Lynch, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid4273949 I was hoping you can talk about pricing strategy for ALXN1210, given the convenience advantage, non-inferiority and also a strong trend in the rate of breakthrough hemolysis. A
nd then, secondly, maybe John, can you talk about whether there's any difference in efficacy among the 3 base -- the weight-based dosing groups? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Yes. With respect to the pricing question, we're not going to comment
 on 1210 pricing. We still have additional data that, as John was saying, will come out in the next 5 to 6 weeks. So we'll wait for that dataset and then we'll move to commercial strategy. But as I said, we're in a strong position. We have a strong clinic
al profile. And I think we will be able to build a strong case for a strong value proposition. And then, on the efficacy, John? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Yes, weight-based. Yes, I think we've looked at efficacy 
across a number of subgroups as well as sensitivity analysis. And we see consistency of results across the board. Bear in mind that we designed the 1210 dosing based on our Phase I/II data to meet a trough concentration that exceeded the threshold that th
e
 model said we needed to reach in order to maximally suppress C5. And we know that the biggest driver of the dose required to get us to that trough concentration is weight. And so the weight was adjusted -- the dose was adjusted based on weight to achieve
 that. And I can say that the PK model confirmed -- PK results confirmed the model that we generated based on the Phase I/II data. We'll have more to say about that in the coming months. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  
\line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Our next question is from Chris Raymond of Piper Jaffray. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Christopher Joseph Raymond}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Piper Jaffray Companies, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid4273949 So just on the transfusion avoidance measure. I think, so with the 20% of patients not needing prior transfusion, that's a population is that's obviously different from the
 Soliris registration data, which I think required patients to have needed transfusion. I know you guys mentioned presenting these data at a medical conference, but just curious if you could say if you saw a similar trend if you back out the patients with
 no history of transfusions? And then, maybe also remind us why you had patients in this trial with no history of transfusions, which is, I think, different from the registration population for Soliris? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 
Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Yes. So the TRIUMPH study required all patients to have had at least 4 transfusions in the prior year coming in. So everybody was -- had a history of transfusion. The rate of transfusion avoidance in that study was 51% versus 0% in the co
ntrol arm, the placebo arm. So we had to make some assumptions for this study because we wanted to have a population that was reflective of contemporary PNH na\'ef
ve patients that included history of no transfusions despite the fact that they had clone sizes 
that matched the broader population indicating they had very active disease. And so in our discussions with the health authorities when we arrived at transfusion avoidance as one of the co-primary endpoints as being really clinically relevant, we wanted t
o
 ensure that we had enough transfusion-dependent patients. And so we capped the transfusion independent group to 20%, so that we would be able to show that difference. The numbers were pretty close to what we expected, as we saw, 66% transfusion avoidance
 with Soliris and about 74% for 1210. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
But the sensitivity analysis, John, showed that the results are robust across patient demographics and patient types. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
That's right. We've done sensitivity and subgroup analyses, sensitivity analyses per -- protocol, for stratification factors as well as subgroup analyses across demographic factors, gender, and all the results are consistent. \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Our next question is from Geoff Meacham of Barclays. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Evan David Seigerman}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Barclays Bank PLC, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid4273949 This is Evan on for Geoff. When you look at the opportunity for 1210, where do you see the greater potential? In patients who are na\'efve 
to treatment as in the data we saw today? Or in SWITCH patients? And then, also, remind us if you need the aHUS data to submit the initial BLA, or if you're going to add that in as an sBLA? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949 
 \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Yes. I think the -- as I
 said, we have a strong case for a potential facilitated conversion. And I laid out why I believe that we have a strong case. And the way I think about this, this would be across different patient types, treatment na\'ef
ves or switch. The number of infusions 
is clinically relevant. The low breakthrough rates with 1210 is clinically relevant. A subcu development is clinically relevant and so on and so on. So I believe -- I don't think that we're going to focus on a specific patient type for 1210. And with resp
ect to your other question... \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Question of filing, yes, we plan to go ahead with the PNH as the initial filing and follow that subsequently with an sBLA for atypical HUS. As we said, we 
plan to file with both the 301 and the 302 studies. We're now about 3 quarters enrolled with atypical HUS Phase III study. And we expect to share the results in the fourth quarter this year. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Evan David Seigerman}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 
Barclays Bank PLC, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
And then, how do these results inform the development of the subcu formulation because I remember you saying that we have to get this data, essentially, to talk more about that? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development
}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Yes.
 I think, as we've said before, the design of the subcu program, which bridges to the IV formulation, is pretty set. We've got agreement based on feedback from both EMA and FDA with regard to that design. We said roughly just over 100 patients required fo
r that study, PK-based looking at trough concentrations as a basis for registration in both PNH and atypical HUS. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 
Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 So the sequence is going to be -- well, hopefully, that's our objective: PNH first, aHUS second and then subcu, subcu with, hopefully, an indication for both PNH and aHUS. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Our next question is Andrew Peters of Deutsche Bank. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Carlos Efrain Solorzano-Say}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Deutsche Bank AG, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid4273949 This is Carlos in for Andrew. Just, I gues
s, following this strong data today, what additional indications do you see for 1210 besides PNH and aHUS? And then, maybe if you could also comment a little bit on the -- on your rationale for the hierarchical testing of the endpoints for superiority? Ob
viously, I mean, from our conversations with experts, indeed, breakthrough hemolysis is one of the key endpoints that they're looking at, but just want to hear your thoughts on that. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line 
 \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 
Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 So
 the additional indications, yes, so we've said previously that we do plan to proceed with a study in myasthenia gravis. The design of that is still under discussion. And the plan is to potentially launch that study later this year. We've also said that w
e
 are exploring a proof of concept study in IgA nephropathy due to begin later this year. Again, the design and the specifics of that program are still under discussion, and we'll have more to share later this year. With regard to superiority testing, I th
i
nk, coming into the study, we felt that powering it for superiority would have exploded the sample size way beyond what we did. And this a study that's the largest that's ever been conducted, nearly 250 patients, with another nearly 200 patients in the 30
2 study. Largest program by far that's ever been conducted in PNH. And we think the data is very robust and consistent and allows us to differentiate 1210 from eculizumab. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Our next question is from Yatin Suneja of SunTrust Bank. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Yatin  Suneja}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 SunTrust Robinson Humphrey, Inc., Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid4273949 Just going back on the breakthrough hemolysis, could you maybe talk about like what do you think might be driving the numerically better reduction in breakthrough hemolysis? And for patient th
at had -- that still had breakthrough hemolysis, is it still a C5 issue? Or is it more from extravascular hemolysis? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 So with regard to what's driving, we're still in the process of ana
lyzing data in more detail to look at when those events occurred in relation to dosing. But the whole premise here is that we have designed 1210 dosing regimen to exceed a trough concentration threshold. So that we have coverage across the entire dosing i
n
terval, even though we're extending it from 2 weeks to 8 weeks, that we get better coverage, better suppression of C5 reductions in LDH and preventing what we have observed, at least anecdotally, occasional patients with Soliris experiencing, at the end o
f
 the dosing interval, PK-based breakthrough. So that was the whole premise around the dose and dosing regimen selected for 1210. And again, further analysis of the data will hopefully bear that out. With regard to C5, again, a lot of that is speculation. 
T
his is largely we're seeing reductions down to 99.9%, and we're seeing LDH down into the normal range, and so this is a change. I think the extravascular hemolysis issue that you mentioned is something that it isn't something that is quantifiable at this 
point and does not seem to correlate with the dose and the dosing interval. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 And we will take 2 more questions. Our next question is from Laura Chico of Raymond James. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Laura Kathryn Chico}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 
Raymond James & Associates, Inc., Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
I guess, one question related to reimbursement strategy. So we've seen other orphan disease companies pursue some broad portfolio-wide reimbursement arrangements that cover multiple assets. And I'm just curious, given the fact now that you've got S
oliris in multiple indications, you're advancing ALXN1210, and then you'll also be pursuing the subcu format, would you consider kind of pursuing a broad portfolio reimbursement strategy? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  
\line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Yes. So I'm not going to c
omment specifically on our reimbursement strategy. This is also going to be part of our pricing strategy. But what I can tell you is the way I think about the portfolio that we have is that each product is unique in what it's doing and there is no interch
a
ngeability for the disease areas that we're treating. So the value that we're bringing to our patients and also to the health care system is through each individual product. And that's the way we think about our portfolio. We're not in a commodity setting
. And I'm going to stop here, as I said, because this is part of pricing reimbursement strategy. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 
Laura Kathryn Chico}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Raymond James & Associates, Inc., Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Okay. And if I could get one quick follow-up. I guess, carrying forward with th
at, you've previously discussed elevating the competitive bar versus also biosimilars. I'm just curious if you can comment in terms of how you view this na\'ef
ve dataset in that context and kind of how it fares to your expectations heading into the readout? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 
Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Yes. So the -- our strategy, as I said before, is we have an offensive play and we have a defensive play. Offensive play is 1210 and building a strong case for potential differentiation. And that's how 301 in next m
onth or the month after 302 will come into play. Our defensive play is our IP strategy, and we discussed where we are on U.S., Japan and where we are in the process of, hopefully, also achieving a similar outcome in Europe. So that's the way that we think
 about our business. So I believe that we're on a strong path to ensure sustainability of our leadership position in C5 complement, PNH, HUS with that strategy. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 
\af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Our next question is from Kennen MacKay of RBC Capital Markets. 
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Kennen B. MacKay}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid4273949 RBC Capital Markets, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
One for John. I wanted to see if there was flexibility in Soliris dosing in this trial the way that there was in the SWITCH trial, with potential to give the Soliris dose a day or 2 earlier if these patient
s are experiencing some kind of PK-related breakthrough? And just wanted to get a sense of how frequently this occurred, and whether this could change the timing of when the Soliris doses were given as it related to when LDH measurements were getting take
n
 every 2 weeks? And whether that was something that could be driving sort of a lower rate of measured LDH breakthroughs on the Soliris arm, given that LDH may start getting measured mid-cycle as opposed to just to ahead of the Soliris patients' next dose?
 \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
So investigators were required to follow the labeled dosing for Soliris for PNH, which is a 14 plus or minus 2-day dosing interval. We can say, having looked at the data, that, virtual
ly, everyone was following that, the 14 days. So there was no ability to alter the dosing interval beyond what's labeled as well as the dose. And in the event of a breakthrough hemolysis, patients were supported symptomatically. And the measurement of LDH
 
is actually done prior to the infusion. So every 2 weeks pre-infusion, that's when LDH was measured for eculizumab. And of course, for 1210, they were only infused every 8 weeks, but those 8-week doses coincide with a 2-week interval for eculizumab. So th
ere were 3 of them versus roughly 12 for the eculizumab arm. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Kennen B. MacKay}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 RBC Capital Markets, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid4273949 Got you. So if those patients were getting it 2 days early on sort of day 12, that's still when the LDH would get measured? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 John J. Orloff}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 Executive VP and Head of Research & Development}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Correct. Yes, they would've come into the clinic for that infusion and we would have measured LDH there, but very few patients actually did that. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Ludwig N. Hantson}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid4273949 CEO & Director}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 Yes
. I think we're going to end the call here. And as we said, we're really pleased with the results. And I'm really, really proud of what the team has done. So Lori and team and everybody at Alexion who worked on this, well done. So thank you for that. 
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid4273949 Operator}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program, and you may all disconnect. Everyone, have a great day. \line \sect }\sectd \ltrsect
\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\footerr \ltrpar \ltrrow\trowd \ltrrow
\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid4273949 \cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid4273949 \trowd \ltrrow
\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \ltrrow
\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\pard\plain \ltrpar
\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf21\insrsid4273949 COPYRIGHT \'a9
 2019 S&P Global Market Intelligence, a division of S&P Global Inc. All rights reserved.\cell }\pard \ltrpar\s15\qr \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid4273949 
PAGE}}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid4273949 18}}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid4273949 \cell 
}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs18\cf21\insrsid4273949 \trowd \ltrrow\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt
\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \lastrow \ltrrow
\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid4273949 HYPERLINK "http://www.marketintelligence.sglobal.com" }}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf21\insrsid4273949 spglobal.com/marketintelligence }}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid4273949 \cell }\pard\plain \ltrpar
\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid4273949 
\trowd \lastrow \ltrrow\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row }\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid4273949 
\par }}\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949 Copyright 
\'a9 2019 by S&P Global Market Intelligence, a division of S&P Global Inc. All rights reserved. \line  \line  \line 
These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable. No content (including index data, ratings, credit-related analy
ses and data, research, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without t
h
e prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, (collectively S&P Global Parties)
 
do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content. THE CONTENT IS PROVI
D
ED ON "AS IS" BASIS. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT TH
E
 CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive,
 
special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the pos
s
ibility of such damages. S&P Global Market Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any secur
i
ties or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence may provide index data. Direct investment in an index is not possible. Exposure to an asset class represented by an index is avail
a
ble through investable instruments based on that index. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judg
m
ent and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. S&
P
 Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to oth
er S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain nonpublic information received in connection with each analytical process. \line  \line  \line 
S&P Global may receive compensation for its ratings and ce
rtain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoor
s
.com  (free of charge), and www.ratingsdirect.com  and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fe
es is available at www.standardandpoors.com/usratingsfees. \line \'a9 2019 S&P Global Market Intelligence. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid4273949 
\par }{\*\themedata 504b030414000600080000002100e9de0fbfff0000001c020000130000005b436f6e74656e745f54797065735d2e786d6cac91cb4ec3301045f748fc83e52d4a
9cb2400825e982c78ec7a27cc0c8992416c9d8b2a755fbf74cd25442a820166c2cd933f79e3be372bd1f07b5c3989ca74aaff2422b24eb1b475da5df374fd9ad
5689811a183c61a50f98f4babebc2837878049899a52a57be670674cb23d8e90721f90a4d2fa3802cb35762680fd800ecd7551dc18eb899138e3c943d7e503b6
b01d583deee5f99824e290b4ba3f364eac4a430883b3c092d4eca8f946c916422ecab927f52ea42b89a1cd59c254f919b0e85e6535d135a8de20f20b8c12c3b0
0c895fcf6720192de6bf3b9e89ecdbd6596cbcdd8eb28e7c365ecc4ec1ff1460f53fe813d3cc7f5b7f020000ffff0300504b030414000600080000002100a5d6
a7e7c0000000360100000b0000005f72656c732f2e72656c73848fcf6ac3300c87ef85bd83d17d51d2c31825762fa590432fa37d00e1287f68221bdb1bebdb4f
c7060abb0884a4eff7a93dfeae8bf9e194e720169aaa06c3e2433fcb68e1763dbf7f82c985a4a725085b787086a37bdbb55fbc50d1a33ccd311ba548b6309512
0f88d94fbc52ae4264d1c910d24a45db3462247fa791715fd71f989e19e0364cd3f51652d73760ae8fa8c9ffb3c330cc9e4fc17faf2ce545046e37944c69e462
a1a82fe353bd90a865aad41ed0b5b8f9d6fd010000ffff0300504b0304140006000800000021006b799616830000008a0000001c0000007468656d652f746865
6d652f7468656d654d616e616765722e786d6c0ccc4d0ac3201040e17da17790d93763bb284562b2cbaebbf600439c1a41c7a0d29fdbd7e5e38337cedf14d59b
4b0d592c9c070d8a65cd2e88b7f07c2ca71ba8da481cc52c6ce1c715e6e97818c9b48d13df49c873517d23d59085adb5dd20d6b52bd521ef2cdd5eb9246a3d8b
4757e8d3f729e245eb2b260a0238fd010000ffff0300504b030414000600080000002100b6f4679893070000c9200000160000007468656d652f7468656d652f
7468656d65312e786d6cec59cd8b1bc915bf07f23f347d97f5d5ad8fc1f2a24fcfda33b6b164873dd648a5eef2547789aad28cc56208de532e81c026e49085bd
ed21842cecc22eb9e48f31d8249b3f22afaa5bdd5552c99e191c3061463074977eefd5afde7bf5de53d5ddcf5e26d4bbc05c1096f6fcfa9d9aefe174ce16248d
7afeb3d9a4d2f13d2151ba4094a5b8e76fb0f03fbbf7eb5fdd454732c609f6403e1547a8e7c752ae8eaa5531876124eeb0154ee1bb25e30992f0caa3ea82a34b
d09bd06aa3566b55134452df4b51026a1f2f97648ebd9952e9dfdb2a1f53784da5500373caa74a35b6243476715e5708b11143cabd0b447b3eccb3609733fc52
fa1e4542c2173dbfa6fffceabdbb5574940b517940d6909be8bf5c2e17589c37f49c3c3a2b260d823068f50bfd1a40e53e6edc1eb7c6ad429f06a0f91c569a71
b175b61bc320c71aa0ecd1a17bd41e35eb16ded0dfdce3dc0fd5c7c26b50a63fd8c34f2643b0a285d7a00c1feee1c3417730b2f56b50866fede1dbb5fe28685b
fa3528a6243ddf43d7c25673b85d6d0159327aec8477c360d26ee4ca4b144443115d6a8a254be5a1584bd00bc6270050408a24493db959e1259a43140f112567
9c7827248a21f056286502866b8ddaa4d684ffea13e827ed5174849121ad780113b137a4f87862cec94af6fc07a0d537206f7ffef9cdeb1fdfbcfee9cd575fbd
79fdf77c6eadca923b466964cafdf2dd1ffef3cd6fbd7ffff0ed2f5fff319b7a172f4cfcbbbffdeedd3ffef93ef5b0e2d2146ffff4fdbb1fbf7ffbe7dfffebaf
5f3bb4f7393a33e1339260e13dc297de5396c0021dfcf119bf9ec42c46c494e8a791402952b338f48f656ca11f6d10450edc00db767cce21d5b880f7d72f2cc2
d398af2571687c182716f094313a60dc6985876a2ec3ccb3751ab927e76b13f714a10bd7dc43945a5e1eaf579063894be530c616cd2714a5124538c5d253dfb1
738c1dabfb8210cbaea764ce99604be97d41bc01224e93ccc899154da5d03149c02f1b1741f0b7659bd3e7de8051d7aa47f8c246c2de40d4417e86a965c6fb68
2d51e252394309350d7e8264ec2239ddf0b9891b0b099e8e3065de78818570c93ce6b05ec3e90f21cdb8dd7e4a37898de4929cbb749e20c64ce4889d0f6394ac
5cd829496313fbb938871045de13265df05366ef10f50e7e40e941773f27d872f787b3c133c8b026a53240d4376beef0e57dccacf89d6ee8126157aae9f3c44a
b17d4e9cd131584756689f604cd1255a60ec3dfbdcc160c05696cd4bd20f62c82ac7d815580f901dabea3dc5027a25d5dcece7c91322ac909de2881de073bad9
493c1b9426881fd2fc08bc6eda7c0ca52e7105c0633a3f37818f08f480102f4ea33c16a0c308ee835a9fc4c82a60ea5db8e375c32dff5d658fc1be7c61d1b8c2
be04197c6d1948eca6cc7b6d3343d49aa00c9819822ec3956e41c4727f29a28aab165b3be596f6a62ddd00dd91d5f42424fd6007b4d3fb84ffbbde073a8cb77f
f9c6b10f3e4ebfe3566c25ab6b763a8792c9f14e7f7308b7dbd50c195f904fbfa919a175fa04431dd9cf58b73dcd6d4fe3ffdff73487f6f36d2773a8dfb8ed64
7ce8306e3b99fc70e5e3743265f3027d8d3af0c80e7af4b14f72f0d46749289dca0dc527421ffc08f83db398c0a092d3279eb838055cc5f0a8ca1c4c60e1228e
b48cc799fc0d91f134462b381daafb4a492472d591f0564cc0a1911e76ea5678ba4e4ed9223becacd7d5c16656590592e5782d2cc6e1a04a66e856bb3cc02bd4
6bb6913e68dd1250b2d721614c6693683a48b4b783ca48fa58178ce620a157f65158741d2c3a4afdd6557b2c805ae115f8c1edc1cff49e1f06200242701e07cd
f942f92973f5d6bbda991fd3d3878c69450034d8db08283ddd555c0f2e4fad2e0bb52b78da2261849b4d425b46377822869fc17974aad1abd0b8aeafbba54b2d
7aca147a3e08ad9246bbf33e1637f535c8ede6069a9a9982a6de65cf6f35430899395af5fc251c1ac363b282d811ea3717a211dcbccc25cf36fc4d32cb8a0b39
4222ce0cae934e960d122231f728497abe5a7ee1069aea1ca2b9d51b90103e59725d482b9f1a3970baed64bc5ce2b934dd6e8c284b67af90e1b35ce1fc568bdf
1cac24d91adc3d8d1797de195df3a708422c6cd795011744c0dd413db3e682c0655891c8caf8db294c79da356fa3740c65e388ae62945714339967709dca0b3a
faadb081f196af190c6a98242f8467912ab0a651ad6a5a548d8cc3c1aafb6121653923699635d3ca2aaa6abab39835c3b60cecd8f26645de60b53531e434b3c2
67a97b37e576b7b96ea74f28aa0418bcb09fa3ea5ea12018d4cac92c6a8af17e1a56393b1fb56bc776811fa07695226164fdd656ed8edd8a1ae19c0e066f54f9
416e376a6168b9ed2bb5a5f5adb979b1cdce5e40f2184197bba6526857c2c92e47d0104d754f92a50dd8222f65be35e0c95b73d2f3bfac85fd60d80887955a27
1c57826650ab74c27eb3d20fc3667d1cd66ba341e31514161927f530bbb19fc00506dde4f7f67a7cefee3ed9ded1dc99b3a4caf4dd7c5513d777f7f5c6e1bb7b
8f40d2f9b2d598749bdd41abd26df627956034e854bac3d6a0326a0ddba3c9681876ba9357be77a1c141bf390c5ae34ea5551f0e2b41aba6e877ba9576d068f4
8376bf330efaaff23606569ea58fdc16605ecdebde7f010000ffff0300504b0304140006000800000021000dd1909fb60000001b010000270000007468656d65
2f7468656d652f5f72656c732f7468656d654d616e616765722e786d6c2e72656c73848f4d0ac2301484f78277086f6fd3ba109126dd88d0add40384e4350d36
3f2451eced0dae2c082e8761be9969bb979dc9136332de3168aa1a083ae995719ac16db8ec8e4052164e89d93b64b060828e6f37ed1567914b284d262452282e
3198720e274a939cd08a54f980ae38a38f56e422a3a641c8bbd048f7757da0f19b017cc524bd62107bd5001996509affb3fd381a89672f1f165dfe514173d985
0528a2c6cce0239baa4c04ca5bbabac4df000000ffff0300504b01022d0014000600080000002100e9de0fbfff0000001c020000130000000000000000000000
0000000000005b436f6e74656e745f54797065735d2e786d6c504b01022d0014000600080000002100a5d6a7e7c0000000360100000b00000000000000000000
000000300100005f72656c732f2e72656c73504b01022d00140006000800000021006b799616830000008a0000001c0000000000000000000000000019020000
7468656d652f7468656d652f7468656d654d616e616765722e786d6c504b01022d0014000600080000002100b6f4679893070000c92000001600000000000000
000000000000d60200007468656d652f7468656d652f7468656d65312e786d6c504b01022d00140006000800000021000dd1909fb60000001b01000027000000
000000000000000000009d0a00007468656d652f7468656d652f5f72656c732f7468656d654d616e616765722e786d6c2e72656c73504b050600000000050005005d010000980b00000000}
{\*\colorschememapping 3c3f786d6c2076657273696f6e3d22312e302220656e636f64696e673d225554462d3822207374616e64616c6f6e653d22796573223f3e0d0a3c613a636c724d
617020786d6c6e733a613d22687474703a2f2f736368656d61732e6f70656e786d6c666f726d6174732e6f72672f64726177696e676d6c2f323030362f6d6169
6e22206267313d226c743122207478313d22646b3122206267323d226c743222207478323d22646b322220616363656e74313d22616363656e74312220616363
656e74323d22616363656e74322220616363656e74333d22616363656e74332220616363656e74343d22616363656e74342220616363656e74353d22616363656e74352220616363656e74363d22616363656e74362220686c696e6b3d22686c696e6b2220666f6c486c696e6b3d22666f6c486c696e6b222f3e}
{\*\latentstyles\lsdstimax375\lsdlockeddef0\lsdsemihiddendef0\lsdunhideuseddef0\lsdqformatdef0\lsdprioritydef0{\lsdlockedexcept \lsdqformat1 \lsdlocked0 Normal;\lsdqformat1 \lsdlocked0 heading 1;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 2;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 3;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 4;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 5;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 6;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 7;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 8;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 9;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 caption;\lsdqformat1 \lsdlocked0 Title;
\lsdqformat1 \lsdlocked0 Subtitle;\lsdqformat1 \lsdlocked0 Strong;\lsdqformat1 \lsdlocked0 Emphasis;\lsdsemihidden1 \lsdpriority99 \lsdlocked0 Placeholder Text;\lsdqformat1 \lsdpriority1 \lsdlocked0 No Spacing;\lsdpriority60 \lsdlocked0 Light Shading;
\lsdpriority61 \lsdlocked0 Light List;\lsdpriority62 \lsdlocked0 Light Grid;\lsdpriority63 \lsdlocked0 Medium Shading 1;\lsdpriority64 \lsdlocked0 Medium Shading 2;\lsdpriority65 \lsdlocked0 Medium List 1;\lsdpriority66 \lsdlocked0 Medium List 2;
\lsdpriority67 \lsdlocked0 Medium Grid 1;\lsdpriority68 \lsdlocked0 Medium Grid 2;\lsdpriority69 \lsdlocked0 Medium Grid 3;\lsdpriority70 \lsdlocked0 Dark List;\lsdpriority71 \lsdlocked0 Colorful Shading;\lsdpriority72 \lsdlocked0 Colorful List;
\lsdpriority73 \lsdlocked0 Colorful Grid;\lsdpriority60 \lsdlocked0 Light Shading Accent 1;\lsdpriority61 \lsdlocked0 Light List Accent 1;\lsdpriority62 \lsdlocked0 Light Grid Accent 1;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 1;
\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 1;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 1;\lsdsemihidden1 \lsdpriority99 \lsdlocked0 Revision;\lsdqformat1 \lsdpriority34 \lsdlocked0 List Paragraph;
\lsdqformat1 \lsdpriority29 \lsdlocked0 Quote;\lsdqformat1 \lsdpriority30 \lsdlocked0 Intense Quote;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 1;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 1;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 1;
\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 1;\lsdpriority70 \lsdlocked0 Dark List Accent 1;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 1;\lsdpriority72 \lsdlocked0 Colorful List Accent 1;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 1;
\lsdpriority60 \lsdlocked0 Light Shading Accent 2;\lsdpriority61 \lsdlocked0 Light List Accent 2;\lsdpriority62 \lsdlocked0 Light Grid Accent 2;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 2;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 2;
\lsdpriority65 \lsdlocked0 Medium List 1 Accent 2;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 2;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 2;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 2;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 2;
\lsdpriority70 \lsdlocked0 Dark List Accent 2;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 2;\lsdpriority72 \lsdlocked0 Colorful List Accent 2;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 2;\lsdpriority60 \lsdlocked0 Light Shading Accent 3;
\lsdpriority61 \lsdlocked0 Light List Accent 3;\lsdpriority62 \lsdlocked0 Light Grid Accent 3;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 3;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 3;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 3;
\lsdpriority66 \lsdlocked0 Medium List 2 Accent 3;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 3;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 3;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 3;\lsdpriority70 \lsdlocked0 Dark List Accent 3;
\lsdpriority71 \lsdlocked0 Colorful Shading Accent 3;\lsdpriority72 \lsdlocked0 Colorful List Accent 3;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 3;\lsdpriority60 \lsdlocked0 Light Shading Accent 4;\lsdpriority61 \lsdlocked0 Light List Accent 4;
\lsdpriority62 \lsdlocked0 Light Grid Accent 4;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 4;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 4;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 4;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 4;
\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 4;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 4;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 4;\lsdpriority70 \lsdlocked0 Dark List Accent 4;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 4;
\lsdpriority72 \lsdlocked0 Colorful List Accent 4;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 4;\lsdpriority60 \lsdlocked0 Light Shading Accent 5;\lsdpriority61 \lsdlocked0 Light List Accent 5;\lsdpriority62 \lsdlocked0 Light Grid Accent 5;
\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 5;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 5;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 5;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 5;
\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 5;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 5;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 5;\lsdpriority70 \lsdlocked0 Dark List Accent 5;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 5;
\lsdpriority72 \lsdlocked0 Colorful List Accent 5;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 5;\lsdpriority60 \lsdlocked0 Light Shading Accent 6;\lsdpriority61 \lsdlocked0 Light List Accent 6;\lsdpriority62 \lsdlocked0 Light Grid Accent 6;
\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 6;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 6;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 6;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 6;
\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 6;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 6;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 6;\lsdpriority70 \lsdlocked0 Dark List Accent 6;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 6;
\lsdpriority72 \lsdlocked0 Colorful List Accent 6;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 6;\lsdqformat1 \lsdpriority19 \lsdlocked0 Subtle Emphasis;\lsdqformat1 \lsdpriority21 \lsdlocked0 Intense Emphasis;
\lsdqformat1 \lsdpriority31 \lsdlocked0 Subtle Reference;\lsdqformat1 \lsdpriority32 \lsdlocked0 Intense Reference;\lsdqformat1 \lsdpriority33 \lsdlocked0 Book Title;\lsdsemihidden1 \lsdunhideused1 \lsdpriority37 \lsdlocked0 Bibliography;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority39 \lsdlocked0 TOC Heading;\lsdpriority41 \lsdlocked0 Plain Table 1;\lsdpriority42 \lsdlocked0 Plain Table 2;\lsdpriority43 \lsdlocked0 Plain Table 3;\lsdpriority44 \lsdlocked0 Plain Table 4;
\lsdpriority45 \lsdlocked0 Plain Table 5;\lsdpriority40 \lsdlocked0 Grid Table Light;\lsdpriority46 \lsdlocked0 Grid Table 1 Light;\lsdpriority47 \lsdlocked0 Grid Table 2;\lsdpriority48 \lsdlocked0 Grid Table 3;\lsdpriority49 \lsdlocked0 Grid Table 4;
\lsdpriority50 \lsdlocked0 Grid Table 5 Dark;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 1;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 1;
\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 1;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 1;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 1;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 1;
\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 1;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 2;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 2;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 2;
\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 2;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 2;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 2;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 2;
\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 3;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 3;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 3;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 3;
\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 3;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 3;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 3;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 4;
\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 4;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 4;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 4;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 4;
\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 4;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 4;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 5;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 5;
\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 5;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 5;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 5;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 5;
\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 5;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 6;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 6;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 6;
\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 6;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 6;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 6;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 6;
\lsdpriority46 \lsdlocked0 List Table 1 Light;\lsdpriority47 \lsdlocked0 List Table 2;\lsdpriority48 \lsdlocked0 List Table 3;\lsdpriority49 \lsdlocked0 List Table 4;\lsdpriority50 \lsdlocked0 List Table 5 Dark;
\lsdpriority51 \lsdlocked0 List Table 6 Colorful;\lsdpriority52 \lsdlocked0 List Table 7 Colorful;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 1;\lsdpriority47 \lsdlocked0 List Table 2 Accent 1;\lsdpriority48 \lsdlocked0 List Table 3 Accent 1;
\lsdpriority49 \lsdlocked0 List Table 4 Accent 1;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 1;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 1;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 1;
\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 2;\lsdpriority47 \lsdlocked0 List Table 2 Accent 2;\lsdpriority48 \lsdlocked0 List Table 3 Accent 2;\lsdpriority49 \lsdlocked0 List Table 4 Accent 2;
\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 2;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 2;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 2;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 3;
\lsdpriority47 \lsdlocked0 List Table 2 Accent 3;\lsdpriority48 \lsdlocked0 List Table 3 Accent 3;\lsdpriority49 \lsdlocked0 List Table 4 Accent 3;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 3;
\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 3;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 3;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 4;\lsdpriority47 \lsdlocked0 List Table 2 Accent 4;
\lsdpriority48 \lsdlocked0 List Table 3 Accent 4;\lsdpriority49 \lsdlocked0 List Table 4 Accent 4;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 4;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 4;
\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 4;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 5;\lsdpriority47 \lsdlocked0 List Table 2 Accent 5;\lsdpriority48 \lsdlocked0 List Table 3 Accent 5;
\lsdpriority49 \lsdlocked0 List Table 4 Accent 5;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 5;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 5;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 5;
\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 6;\lsdpriority47 \lsdlocked0 List Table 2 Accent 6;\lsdpriority48 \lsdlocked0 List Table 3 Accent 6;\lsdpriority49 \lsdlocked0 List Table 4 Accent 6;
\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 6;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 6;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 6;\lsdsemihidden1 \lsdunhideused1 \lsdpriority99 \lsdlocked0 Mention;
\lsdsemihidden1 \lsdunhideused1 \lsdpriority99 \lsdlocked0 Smart Hyperlink;\lsdsemihidden1 \lsdunhideused1 \lsdpriority99 \lsdlocked0 Hashtag;\lsdsemihidden1 \lsdunhideused1 \lsdpriority99 \lsdlocked0 Unresolved Mention;}}{\*\datastore }}